Department of Pediatrics and Child Health, Jimma University, Jimma, Ethiopia.
College of Social Sciences and Humanities, Jimma University, Jimma, Ethiopia.
PLoS One. 2021 Aug 9;16(8):e0255210. doi: 10.1371/journal.pone.0255210. eCollection 2021.
Of 2.5 million newborn deaths each year, serious neonatal infections are a leading cause of neonatal death for which inpatient treatment is recommended. However, manysick newborns in sub-Saharan Africa and south Asia do not have access to inpatientcare. A World Health Organization (WHO) guideline recommends simplified antibiotic treatment atan outpatient level for young infants up to two months of age with possible serious bacterial infection (PSBI), when referral is not feasible.We implemented this guidelinein Ethiopia to increase coverage of treatment and to learn about potential facilitating factors and barriers for implementation.
We conducted implementation research in two districts (Tiro Afata and Gera) in Jimma Zone, Ethiopia, to learn about the feasibility of implementing the WHO PSBI guideline within a programme setting using the existing health care structure. We conducted orientation meetings and policy dialogue with key stakeholders and trained health extension workers and health centre staff to identify and manage sick young infants with PSBI signs at a primary health care unit. We established a Technical Support Unit (TSU) to facilitate programme learning, built health workers' capacity and provided support for quality control, monitoring and data collection.We sensitized the community to appropriate care-seeking and supported the health care system in implementation. The research team collected data using structured case recording forms.
From September 2016 to August 2017, 6185 live births and 601 sick young infants 0-59 days of age with signs of PSBI were identified. Assuming that 25% of births were missed (total births 7731) and 10% of births had an episode of PSBI in the first two months of life, the coverage of appropriate treatment for PSBI was 77.7% (601/773). Of 601 infants with PSBI, fast breathing only (pneumonia) was recorded in 432 (71.9%) infants 7-59 days of age; signs of clinical severe infection (CSI) in 155 (25.8%) and critical illnessin 14 (2.3%). Of the 432 pneumonia cases who received oral amoxicillin treatment without referral, 419 (97.0%) were successfully treated without any deaths. Of 169 sick young infants with either CSI or critical illness, only 110 were referred to a hospital; 83 did not accept referral advice and received outpatient injectable gentamicin plus oral amoxicillin treatment either at a health post or health centre. Additionally, 59 infants who should have been referred, but were not received injectable gentamicin plus oral amoxicillin outpatient treatment. Of infants with CSI, 129 (82.2%) were successfully treated as outpatients, while two died (1.3%). Of 14 infants with critical illness, the caregivers of five accepted referral to a hospital, and nine were treated with simplified antibiotics on an outpatient basis. Two of 14 (14.3%) infants with critical illness died within 14 days of initial presentation.
In settings where referral to a hospital is not feasible, young infants with PSBI can be treated on an outpatient basis at either a health post or health centre, which can contribute to saving many lives. Scaling-up will require health system strengthening including community mobilization.
Trial is registered on Australian New Zealand Clinical Trials registry (ANZCTR) ACTRN12617001373369.
每年有 250 万新生儿死亡,严重的新生儿感染是导致新生儿死亡的主要原因,建议对此类感染进行住院治疗。然而,撒哈拉以南非洲和南亚地区的许多患病新生儿无法获得住院治疗。世界卫生组织(WHO)指南建议对可能患有严重细菌感染(PSBI)的 2 个月以下的年轻婴儿在门诊水平进行简化抗生素治疗,而无法进行转介。我们在埃塞俄比亚实施了该指南,以增加治疗覆盖率,并了解实施该指南的潜在促进因素和障碍。
我们在吉姆马地区的两个区(Tiro Afata 和 Gera)进行了实施研究,以了解在现有医疗保健结构内实施世卫组织 PSBI 指南的可行性,该指南用于方案设置。我们与主要利益攸关方举行了定向会议和政策对话,并培训了卫生延伸工作者和卫生中心工作人员,以在初级保健单位识别和管理患有 PSBI 症状的患病年轻婴儿。我们建立了一个技术支持股(TSU),以促进方案学习,建立卫生工作者的能力,并为质量控制、监测和数据收集提供支持。我们使社区对适当的护理有了认识,并支持医疗保健系统的实施。研究小组使用结构化病例记录表格收集数据。
从 2016 年 9 月至 2017 年 8 月,共发现 6185 例活产和 601 名 0-59 天有 PSBI 症状的患病年轻婴儿。假设 25%的分娩被遗漏(总分娩 7731 例),并且 10%的分娩在前两个月发生 PSBI,那么 PSBI 的适当治疗覆盖率为 77.7%(601/773)。在 601 名患有 PSBI 的婴儿中,7-59 天的婴儿中有 432 名(71.9%)有呼吸急促(肺炎)的记录;155 名(25.8%)有临床严重感染(CSI)迹象,14 名(2.3%)有危急疾病。在 432 例接受口服阿莫西林治疗而无需转介的肺炎病例中,419 例(97.0%)成功治疗,无任何死亡。在 169 名患有 CSI 或危急疾病的患病年轻婴儿中,只有 110 名被转介到医院;83 名不接受转介建议,在卫生所或卫生中心接受了肌内注射庆大霉素加口服阿莫西林治疗。此外,还有 59 名应转介但未接受肌内注射庆大霉素加口服阿莫西林门诊治疗的婴儿。在 CSI 婴儿中,129 名(82.2%)成功接受门诊治疗,2 名死亡(1.3%)。在 14 名患有危急疾病的婴儿中,有 5 名照顾者接受了转院至医院的建议,有 9 名婴儿在门诊接受了简化抗生素治疗。在最初出现症状后 14 天内,有 2 名(14.3%)患有危急疾病的婴儿死亡。
在无法转介至医院的情况下,患有 PSBI 的婴儿可以在卫生所或卫生中心接受门诊治疗,这有助于挽救许多生命。扩大规模需要加强卫生系统,包括社区动员。
该试验在澳大利亚和新西兰临床试验注册中心(ANZCTR)注册,注册号为 ACTRN12617001373369。